HUP0400153A2 - Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment - Google Patents

Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment

Info

Publication number
HUP0400153A2
HUP0400153A2 HU0400153A HUP0400153A HUP0400153A2 HU P0400153 A2 HUP0400153 A2 HU P0400153A2 HU 0400153 A HU0400153 A HU 0400153A HU P0400153 A HUP0400153 A HU P0400153A HU P0400153 A2 HUP0400153 A2 HU P0400153A2
Authority
HU
Hungary
Prior art keywords
dihydromikanolide
mikanolide
analogue
combined
product
Prior art date
Application number
HU0400153A
Other languages
English (en)
Inventor
Gregoire Prevost
Helene Coulomb
Olivier Lavergne
Christophe Lanco
Beng-Poon Teng
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of HUP0400153A2 publication Critical patent/HUP0400153A2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0400153A 2001-05-30 2002-05-29 Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment HUP0400153A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0107104A FR2825278A1 (fr) 2001-05-30 2001-05-30 Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
PCT/FR2002/001800 WO2002096348A2 (fr) 2001-05-30 2002-05-29 Produit comprenant du mikanolide ou du dihydromikanolide en association avec un autre agent anti-cancereux

Publications (1)

Publication Number Publication Date
HUP0400153A2 true HUP0400153A2 (en) 2007-07-30

Family

ID=8863791

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400153A HUP0400153A2 (en) 2001-05-30 2002-05-29 Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment

Country Status (13)

Country Link
US (1) US20040138245A1 (hu)
EP (1) EP1438039A2 (hu)
JP (1) JP2004533456A (hu)
KR (1) KR20040025922A (hu)
CN (1) CN1691941A (hu)
AR (1) AR034059A1 (hu)
CA (1) CA2448528A1 (hu)
CZ (1) CZ20033549A3 (hu)
FR (1) FR2825278A1 (hu)
HU (1) HUP0400153A2 (hu)
PL (1) PL369148A1 (hu)
RU (1) RU2003137833A (hu)
WO (1) WO2002096348A2 (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2834289B1 (fr) * 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
CZ2004825A3 (cs) * 2001-12-27 2004-12-15 Société De Conseils De Recherches Et D'application Benzothiazol- a benzoxazol-4,7-dionové deriváty a jejich použití jako inhibitorů cDcC25 fosfatázy
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
FR2856686A1 (fr) * 2003-06-25 2004-12-31 Sod Conseils Rech Applic Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation
TW200536536A (en) 2004-02-25 2005-11-16 Schering Corp Pyrazolotriazines as kinase inhibitors
FR2879460B1 (fr) * 2004-12-17 2007-02-23 Sod Conseils Rech Applic Associations anti-douleur comprenant un derive de dihydroimidazopyrazine
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
TW200806284A (en) * 2006-03-31 2008-02-01 Alcon Mfg Ltd Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
CN101981033B (zh) 2008-02-06 2015-02-04 百时美施贵宝公司 用作激酶抑制剂的取代的咪唑并哒嗪化合物
AR077463A1 (es) 2009-07-09 2011-08-31 Irm Llc Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
CA2978518C (en) * 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
CN106317057B (zh) * 2015-07-02 2019-02-01 北京桦冠医药科技有限公司 具有咪唑并吡嗪类衍生物,其制备及其在医药上的应用
WO2018024172A1 (en) * 2016-08-05 2018-02-08 The University Of Hong Kong Platinum complexes and methods of use thereof
CN110691597A (zh) 2017-04-24 2020-01-14 诺华股份有限公司 2-氨基-1-(2-(4-氟苯基)-3-(4-氟苯基氨基)-8,8-二甲基-5,6-二氢咪唑并[1,2-a]吡嗪-7(8H)-基)乙酮及其组合的治疗方案
CN111484503B (zh) * 2020-01-10 2022-05-27 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种薇甘菊内酯衍生物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07267940A (ja) * 1994-03-29 1995-10-17 Ajinomoto Co Inc 新規な11員環化合物
PT835258E (pt) * 1995-06-21 2003-02-28 Sod Conseils Rech Applic Novos analogos de camptotecina, processos para a sua preparacao, sua utilizacao como farmacos e composicoes farmaceuticas que os contem
ATE284224T1 (de) * 1999-11-09 2004-12-15 Sod Conseils Rech Applic Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterotrimerischen g- proteinen in kombination mit einem anderen anti- krebs mittel zu einer therapeutischen verwendung in der krebsbehandlung
FR2801792B1 (fr) * 1999-12-01 2003-04-18 Sod Conseils Rech Applic Un nouveau medicament, le dihydromikanolide, son obtention par extraction de la plante mikania micrantha et son utilisation comme agent anti-proliferatif

Also Published As

Publication number Publication date
RU2003137833A (ru) 2005-03-27
JP2004533456A (ja) 2004-11-04
US20040138245A1 (en) 2004-07-15
AR034059A1 (es) 2004-01-21
WO2002096348A3 (fr) 2004-05-06
CN1691941A (zh) 2005-11-02
CA2448528A1 (fr) 2002-12-05
CZ20033549A3 (cs) 2004-10-13
PL369148A1 (en) 2005-04-18
FR2825278A1 (fr) 2002-12-06
EP1438039A2 (fr) 2004-07-21
KR20040025922A (ko) 2004-03-26
WO2002096348A2 (fr) 2002-12-05

Similar Documents

Publication Publication Date Title
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
IL179714A (en) Pharmaceutical preparation containing a history of 2-biphenyl-4-ram-3,2-dehydro-1h-quinazoline-4-on and its use in the preparation of cancer drugs and blood vessel formation
IL157993A0 (en) Molecular conjugates for use in cancer treatment and methods for the preparation thereof
IL231810A (en) History of itensinoid and pharmaceutical preparations containing the same methods of preparation and use thereof for cancer treatment
IL174994A0 (en) Pyrimidin - 4 - yl - 3, 4 - thione compounds and their use in therapy
WO2004103301A3 (en) Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
IL202332A0 (en) Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
HK1061679A1 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-ibe derivatives, their preparation and their therapeutic use.
HK1080447B (zh) 視黃醇衍生物、它們在治療癌症和增强其它細胞毒性劑功效中的應用
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
AU2002352799A8 (en) Methods for evaluating drug-resistance gene expression in the cancer patient
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
HUP0400153A2 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
HK1105886A1 (en) Pharmaceutical compositions comprising l-733060 for use in the treatment of cancer tumours l-733060
EP1257255A4 (en) THERAPEUTIC PRODUCT, ITS USE AND MANUFACTURE
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
HUP0300005A3 (en) Modified cytokines for use in cancer therapy
ZA200210316B (en) Composition and its therapeutic use.
AU2002248467A1 (en) Vegf-d expression in brain cancer
AU2002352566A1 (en) Use of corrinoids in the treatment of skin diseases
IL160722A0 (en) Aryloxypropylamines as chemosensitizing agents in the treatment of cancer
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
AU2002313087A1 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
GB0427637D0 (en) Topical formulations for use in the treatment or prevention of skin cancers
IL161859A0 (en) 3-Heteroaryl-3.5-dihydro-4-oxo-4H-pyridazinoÄ4.5-BÜindole-1-carboxamide derivatives, their preparation and therapeutic use

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees